"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B1,US 8439595 B1,109-813-134-994-583,2013-05-14,2013,US 201213385462 A,2012-01-31,US 201213385462 A,2012-01-31,Pre-emplaced electrical vehicle restraint,"A vehicle restraining system using an electrical impulse to disable the control system of a targeted vehicle including a roadway module placed at a location to engage the targeted vehicle for delivering the electrical impulse to the vehicle; a roadside module for generating the energy required for the electrical impulse and delivering the energy to the roadway module; and an operator interface module for operating the restraining system. In addition, a method of disabling the control system of a vehicle by delivering an electrical impulse to the vehicle includes the steps of charging a vehicle restraining system; setting the charged vehicle restraining system to disable the next encountered vehicle; detecting the next encountered vehicle, and delivering the electrical impulse to the targeted vehicle.",CHAPARRO JORDAN E;;DUNCAN MICHAEL R;;DURBIN JOHN R;;US NAVY,CHAPARRO JORDAN E;;DUNCAN MICHAEL R;;DURBIN JOHN R,UNITED STATES OF AMERICA REPRESENTED BY SEC. OF NAVY (2012-01-30),https://lens.org/109-813-134-994-583,Granted Patent,yes,9,6,1,1,0,E01F13/12;;F41H11/08;;F41H13/0018;;E01F13/12;;F41H11/08;;F41H13/0018,G08C19/00;;E01F13/12,404/6;;404/9;;340/12.1,0,0,,,,INACTIVE
2,CN,A,CN 107111599 A,161-241-422-984-974,2017-08-29,2017,CN 201580058970 A,2015-10-15,US 201462073606 P;;US 201514588812 A;;US 2015/0055830 W,2014-10-31,System and method for managing safe downtime of shared resources within PCD,"A method and system for managing safe downtime of shared resources within a portable computing device are described. The method may include determining a tolerance for a downtime period for an unacceptable deadline miss element of the portable computing device. Next, the determined tolerance for the downtime period may be transmitted to quality-of-service (QoS) controller. The QoS controller may determine if the tolerance for the downtime period needs to be adjusted. The QoS controller may receive a downtime request from one or more shared resources of the portable computing device. The QoS controller may determine if the downtime request needs to be adjusted. Next, the QoS controller may select a downtime request for execution and then identify which one or more unacceptable deadline miss elements of the portable computing device that are impacted by the selected downtime request.",QUALCOMM INC,DUROIU CRISTIAN;;GADELRAB SERAG;;CHAMARTY VINOD;;SINHA POOJA;;CHAPARRO JOHN DANIEL;;VOOTUKURU ANIL;;CUPPU VINODH RAMESH;;LEE JOSEPH SCHWEIRAY;;MITTER VINAY;;CHOW PAUL;;LIU RUOLONG;;KUAN JOHNNY JONE WAI;;DROP MICHAEL,,https://lens.org/161-241-422-984-974,Patent Application,no,4,0,5,5,0,G06F15/7814;;H04L47/70;;G06F9/50;;G06F9/5016;;G06F9/505;;G06F3/005;;G06F13/00;;G06F13/1626;;G06F13/14;;G06F13/16;;H04L47/70;;H04L47/783;;H04L47/72;;G06F1/3234;;G06F3/0613;;G06F1/3225;;G06F1/3243;;G06F1/3206;;G06F1/3287;;G06F1/3296;;G06F1/3215;;G06F13/00;;G06F3/061;;G06F1/32;;G06F1/3275;;G06F3/0611;;H04L47/781;;H04L47/78;;H04L47/788;;G06F13/1626;;H04L47/70;;G06F13/14;;G06F13/16;;G06F9/50;;G06F9/5016;;G06F9/505;;G06F3/005,G06F15/78,,0,0,,,,DISCONTINUED
3,US,A1,US 2024/0010696 A1,011-775-015-568-161,2024-01-11,2024,US 202318335259 A,2023-06-15,US 202318335259 A;;US 202363496545 P;;US 202263353241 P,2022-06-17,IL-12 Variants and Uses Thereof,"IL-12 variants are provided. Also provided are antibodies that specifically bind to PD1. Also provided are fusion proteins of IL-12 variants and anti-PD1 antibodies. Also provided are uses of these IL-12 variants, anti-PD1 antibodies, fusion proteins, and related compositions and methods.",PFIZER,APGAR JAMES REASONER;;CHAPARRO RIGGERS JAVIER FERNANDO;;CHU LING HON MATTHEW;;HUANG TZU-HSUAN;;MOHAN KRITIKA;;MOSYAK LIDIA;;PASCUA EDWARD DERRICK;;PATTERSON JAMES TRAVIS;;STARBECK-MILLER GABRIEL ROY;;ZAJONC DIRK MICHAEL,,https://lens.org/011-775-015-568-161,Patent Application,yes,0,0,2,2,0,C07K14/5434;;C07K16/2818;;C07K2319/00;;A61P35/00;;C07K2319/33;;A61K2039/505;;A61K38/00;;A61P35/00;;C07K14/5434;;C07K16/2818;;C07K2317/565;;C12N15/63,C07K14/54;;A61P35/00;;C07K16/28;;C12N15/63,,0,0,,,,PENDING
4,WO,A1,WO 2016/069284 A1,063-432-857-258-065,2016-05-06,2016,US 2015/0055830 W,2015-10-15,US 201462073606 P;;US 201514588812 A,2014-10-31,SYSTEM AND METHOD FOR MANAGING SAFE DOWNTIME OF SHARED RESOURCES WITHIN A PCD,"A method and system for managing safe downtime of shared resources within a portable computing device are described. The method may include determining a tolerance for a downtime period for an unacceptable deadline miss element of the portable computing device. Next, the determined tolerance for the downtime period may be transmitted to quality-of-service (""QoS"") controller. The QoS controller may determine if the tolerance for the downtime period needs to be adjusted. The QoS controller may receive a downtime request from one or more shared resources of the portable computing device. The QoS controller may determine if the downtime request needs to be adjusted. Next, the QoS controller may select a downtime request for execution and then identify which one or more unacceptable deadline miss elements of the portable computing device that are impacted by the selected downtime request.",QUALCOMM INC,DUROIU CRISTIAN;;GADELRAB SERAG;;CHAMARTY VINOD;;SINHA POOJA;;CHAPARRO JOHN DANIEL;;VOOTUKURU ANIL;;CUPPU VINODH RAMESH;;LEE JOSEPH SCHWEIRAY;;MITTER VINAY;;CHOW PAUL;;LIU RUOLONG;;KUAN JOHNNY JONE WAI;;DROP MICHAEL,,https://lens.org/063-432-857-258-065,Patent Application,yes,3,1,5,5,0,G06F15/7814;;H04L47/70;;G06F9/50;;G06F9/5016;;G06F9/505;;G06F3/005;;G06F13/00;;G06F13/1626;;G06F13/14;;G06F13/16;;H04L47/70;;H04L47/783;;H04L47/72;;G06F1/3234;;G06F3/0613;;G06F1/3225;;G06F1/3243;;G06F1/3206;;G06F1/3287;;G06F1/3296;;G06F1/3215;;G06F13/00;;G06F3/061;;G06F1/32;;G06F1/3275;;G06F3/0611;;H04L47/781;;H04L47/78;;H04L47/788;;G06F13/1626;;H04L47/70;;G06F13/14;;G06F13/16;;G06F9/50;;G06F9/5016;;G06F9/505;;G06F3/005,G06F9/50,,0,0,,,,PENDING
5,EP,A1,EP 3213203 A1,093-522-631-178-131,2017-09-06,2017,EP 15801523 A,2015-10-15,US 201462073606 P;;US 201514588812 A;;US 2015/0055830 W,2014-10-31,SYSTEM AND METHOD FOR MANAGING SAFE DOWNTIME OF SHARED RESOURCES WITHIN A PCD,,QUALCOMM INC,DUROIU CRISTIAN;;CHAMARTY VINOD;;GADELRAB SERAG;;DROP MICHAEL;;SINHA POOJA;;LIU RUOLONG;;CHAPARRO JOHN DANIEL;;CUPPU VINODH RAMESH;;LEE JOSEPH SCHWEIRAY;;KUAN JOHNNY JONE WAI;;CHOW PAUL;;VOOTUKURU ANIL;;MITTER VINAY,,https://lens.org/093-522-631-178-131,Patent Application,yes,0,0,5,5,0,G06F15/7814;;H04L47/70;;G06F9/50;;G06F9/5016;;G06F9/505;;G06F3/005;;G06F13/00;;G06F13/1626;;G06F13/14;;G06F13/16;;H04L47/70;;H04L47/783;;H04L47/72;;G06F1/3234;;G06F3/0613;;G06F1/3225;;G06F1/3243;;G06F1/3206;;G06F1/3287;;G06F1/3296;;G06F1/3215;;G06F13/00;;G06F3/061;;G06F1/32;;G06F1/3275;;G06F3/0611;;H04L47/781;;H04L47/78;;H04L47/788;;G06F13/1626;;H04L47/70;;G06F13/14;;G06F13/16;;G06F9/50;;G06F9/5016;;G06F9/505;;G06F3/005,G06F9/50,,0,0,,,,DISCONTINUED
6,US,A1,US 2016/0127259 A1,093-563-030-539-481,2016-05-05,2016,US 201514588812 A,2015-01-02,US 201514588812 A;;US 201462073606 P,2014-10-31,SYSTEM AND METHOD FOR MANAGING SAFE DOWNTIME OF SHARED RESOURCES WITHIN A PCD,"A method and system for managing safe downtime of shared resources within a portable computing device are described. The method may include determining a tolerance for a downtime period for an unacceptable deadline miss element of the portable computing device. Next, the determined tolerance for the downtime period may be transmitted to quality-of-service (“QoS”) controller. The QoS controller may determine if the tolerance for the downtime period needs to be adjusted. The QoS controller may receive a downtime request from one or more shared resources of the portable computing device. The QoS controller may determine if the downtime request needs to be adjusted. Next, the QoS controller may select a downtime request for execution and then identify which one or more unacceptable deadline miss elements of the portable computing device that are impacted by the selected downtime request.",QUALCOMM INC,DUROIU CRISTIAN;;CHAMARTY VINOD;;GADELRAB SERAG;;DROP MICHAEL;;SINHA POOJA;;LIU RUOLONG;;CHAPARRO JOHN DANIEL;;CUPPU VINODH RAMESH;;LEE JOSEPH SCHWEIRAY;;KUAN JOHNNY JONE WAI;;CHOW PAUL;;VOOTUKURU ANIL;;MITTER VINAY,QUALCOMM INCORPORATED (2015-01-07),https://lens.org/093-563-030-539-481,Patent Application,yes,10,5,5,5,0,G06F15/7814;;H04L47/70;;G06F9/50;;G06F9/5016;;G06F9/505;;G06F3/005;;G06F13/00;;G06F13/1626;;G06F13/14;;G06F13/16;;H04L47/70;;H04L47/783;;H04L47/72;;G06F1/3234;;G06F3/0613;;G06F1/3225;;G06F1/3243;;G06F1/3206;;G06F1/3287;;G06F1/3296;;G06F1/3215;;G06F13/00;;G06F3/061;;G06F1/32;;G06F1/3275;;G06F3/0611;;H04L47/781;;H04L47/78;;H04L47/788;;G06F13/1626;;H04L47/70;;G06F13/14;;G06F13/16;;G06F9/50;;G06F9/5016;;G06F9/505;;G06F3/005,H04L12/911,,0,0,,,,DISCONTINUED
7,WO,A1,WO 2023/242769 A1,053-855-808-569-598,2023-12-21,2023,IB 2023056152 W,2023-06-14,US 202263353241 P;;US 202363496545 P,2022-06-17,"IL-12 VARIANTS, ANTI-PD1 ANTIBODIES, FUSION PROTEINS, AND USES THEREOF","IL-12 variants are provided. Also provided are antibodies that specifically bind to PD1. Also provided are fusion proteins of IL-12 variants and anti-PD1 antibodies. Also provided are uses of these IL-12 variants, anti-PD1 antibodies, fusion proteins, and related compositions and methods.",PFIZER,APGAR JAMES REASONER;;CHAPARRO RIGGERS JAVIER FERNANDO;;CHU LING HON MATTHEW;;HUANG TZU-HSUAN;;MOHAN KRITIKA;;MOSYAK LIDIA;;PASCUA EDWARD DERRICK;;PATTERSON JAMES TRAVIS;;STARBECK-MILLER GABRIEL ROY;;ZAJONC DIRK MICHAEL,,https://lens.org/053-855-808-569-598,Patent Application,yes,27,0,2,2,56,C07K14/5434;;C07K16/2818;;C07K2319/00;;A61P35/00;;C07K2319/33;;A61K2039/505;;A61K38/00;;A61P35/00;;C07K14/5434;;C07K16/2818;;C07K2317/565;;C12N15/63,C07K14/54;;A61K38/20;;A61P35/00;;C07K16/28,,65,39,033-733-097-479-033;;008-127-009-315-13X;;033-733-097-479-033;;041-574-287-145-813;;008-274-774-541-556;;099-423-776-471-288;;076-090-519-318-074;;017-150-654-990-340;;004-891-036-744-106;;173-572-222-412-05X;;002-264-966-090-625;;049-134-753-209-354;;024-995-475-936-443;;023-868-377-007-810;;019-130-383-424-869;;005-018-877-991-494;;106-753-778-592-300;;030-630-100-818-462;;002-007-578-507-698;;156-501-805-490-709;;004-529-618-392-612;;068-264-897-850-380;;104-214-218-664-008;;072-509-376-457-062;;010-488-381-022-259;;017-216-732-209-839;;000-513-978-398-020;;013-452-637-389-025;;054-717-629-774-351;;057-945-343-734-358;;002-237-818-610-496;;017-598-779-633-254;;083-695-147-039-802;;127-144-904-319-750;;031-391-134-339-145;;070-318-112-524-781;;031-605-709-605-848;;006-624-122-050-705;;115-888-744-798-778,34376502;;10.1158/2326-6066.cir-21-0058;;10.1172/jci153604;;35104810;;pmc8803347;;34376502;;10.1158/2326-6066.cir-21-0058;;24398568;;10.1038/ncomms4016;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;10.1002/(sici)1097-0134(1999)37:3+<194::aid-prot24>3.3.co;2-6;;10.1002/(sici)1097-0134(1999)37:3+<194::aid-prot24>3.0.co;2-f;;9143687;;10.1146/annurev.immunol.15.1.203;;3140379;;10.1126/science.3140379;;10592229;;pmc102431;;10.1093/nar/28.1.214;;7561440;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;2594766;;pmc298475;;10.1073/pnas.86.23.9268;;17947238;;10.1074/jbc.m706190200;;10.1073/pnas.63.1.78;;5257969;;pmc534037;;1172191;;10.1038/256495a0;;10.1038/348552a0;;2247164;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;8069524;;10.1006/immu.1994.1004;;10.4049/jimmunol.117.2.587;;950463;;10.1016/s0167-5699(97)01172-9;;9425738;;10.1038/nbt0797-637;;9219265;;14699147;;10.1074/jbc.c300470200;;10.1016/0196-8858(81)90046-4;;7490135;;pmc1384012;;8943402;;10.4049/jimmunol.157.11.4963;;10.4049/jimmunol.164.8.4178;;10754313;;2507634;;10.4049/jimmunol.143.8.2595;;9700502;;10.1111/j.1600-065x.1998.tb01188.x;;10.1159/000319352;;10.1159/000425635;;9018875;;10.1016/0161-5890(95)00118-2;;8643100;;10.1021/bi00469a021;;2141793;;10.1016/s0958-1669(96)80116-9;;8768899;;10.1038/6179;;10052355;;10.1016/j.jim.2007.09.017;;pmc2243222;;17996249;;10.1002/med.21530;;30215856;;9916734,"XU YUANMING ET AL: ""An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity"", CANCER IMMUNOLOGY RESEARCH, vol. 9, no. 10, 1 October 2021 (2021-10-01), US, pages 1141 - 1157, XP093054460, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-21-0058;;REN ZHENHUA ET AL: ""Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity"", JOURNAL OF CLINICAL INVESTIGATION, vol. 132, no. 3, 1 February 2022 (2022-02-01), XP055927871, DOI: 10.1172/JCI153604;;XU, Y. ET AL., CANCER IMMUNOL RES, vol. 9, no. 10, 2021, pages 1141 - 1157;;CODARRI DEAK, L. ET AL., NATURE, vol. 610, no. 7930, 2022, pages 173 - 181;;GARCIN, G. ET AL., NAT COMMUN, vol. 5, 2014, pages 3016;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 2003;;PCR 2: A PRACTICAL APPROACH, 1995;;ANTIBODIES, A LABORATORY MANUAL, 1988;;ANIMAL CELL CULTURE, 1987;;OLIGONUCLEOTIDE SYNTHESIS, 1984;;CLYNESET, PROC. NATL. ACAD. SCI. (USA, vol. 95, 1998, pages 652 - 656;;ANIMAL CELL CULTURE, 1987;;""Cell and Tissue Culture Laboratory Procedures"", August 1993, J. WILEY AND SONS;;GENE TRANSFER VECTORS FOR MAMMALIAN CELLS, 1987;;PCR: THE POLYMERASE CHAIN REACTION, 1994;;CURRENT PROTOCOLS IN IMMUNOLOGY, 1991;;SAMUDRALA ET AL.: ""Ab Initio Protein Structure Prediction Using aCombined Hierarchical Approach"", PROTEINS, STRUCTURE, FUNCTION AND GENETICS, vol. 3, 1999, pages 194 - 198, XP001146416;;C. A. JANEWAYP. TRAVERS, IMMUNOBIOLOGY, 1997;;DAERON, ANNU. REV. IMMUNOL., vol. 15, 1997, pages 203 - 234;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;JOHNSONWU, NUCLEIC ACIDS RES., vol. 28, 2000, pages 214 - 8;;DE HAAS ET AL., J. LAB. CLIN. MED., vol. 126, 1995, pages 330 - 41;;HUSTON ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 5879 - 5883;;CHOTHIALESK, J MOL BIOL, vol. 196, no. 4, 1987, pages 901 - 917;;CHOTHIAET, J. MOL. BIOL., vol. 196, 1986, pages 901 - 17;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 83;;MARTIN ET AL., PROC NATL ACAD SCI (USA, vol. 86, 1989, pages 9268 - 9272;;MACCALLUM ET AL., J. MOL. BIOL., vol. 5, 1996, pages 732 - 45;;MAKABE ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, 2008, pages 1156 - 1166;;EDELMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 63, no. 1, 1969, pages 78 - 85;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495;;MCCAFFERTYET, NATURE, vol. 348, 1990, pages 552 - 554;;EUR. J. IMMUNOL., vol. 29, 1999, pages 2613 - 2624;;RAVETCHKINET, ANNU. REV. IMMUNOL, vol. 9, 1991, pages 457 - 92;;CAPEL ET AL., IMMUNOMETHODS, vol. 4, 1994, pages 25 - 34;;GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587;;KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249;;GHETIEWARD, IMMUNOL. TODAY, vol. 18, no. 12, 1997, pages 592 - 598;;GHETIE ET AL., NATURE BIOTECHNOLOGY, vol. 15, no. 7, 1997, pages 637 - 640;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;""Methods in Enzymology"", vol. 266, 1996, ACADEMIC PRESS, INC, article ""Computer Methods for Macromolecular Sequence Analysis"";;METH. MAL. BIOL., vol. 70, 1997, pages 173 - 187;;J. MAL. BIOL., vol. 48, 1970, pages 443 - 453;;SMITHWATERMAN, ADVANCES IN APPLIED MATHEMATICS, vol. 2, 1981, pages 482 - 489;;""Selected Methods and Applications"", 1988, ALAN R. LISS, INC, article ""Current Methods in Sequence Comparison and Analysis, Macromolecule Sequencing and Synthesis"", pages: 127 - 149;;""UniProt"", Database accession no. P42701;;MORGAN ET AL., IMMUNOLOGY, vol. 86, 1995, pages 319 - 324;;LUND ET AL., J. IMMUNOLOGY, vol. 157, 1996, pages 4963 - 4969;;IDUSOGIE ET AL., J. IMMUNOLOGY, vol. 164, 2000, pages 4178 - 4184;;TAO ET AL., J. IMMUNOLOGY, vol. 143, 1989, pages 2595 - 2601;;JEFFERIS ET AL., IMMUNOLOGICAL REVIEWS, vol. 163, 1998, pages 59 - 76;;JEFFERISLUND, CHEM. IMMUNOL., vol. 65, 1997, pages 111 - 128;;WRIGHTMORRISON, TIBTECH, vol. 15, 1997, pages 26 - 32;;BOYD ET AL., MOL. IMMUNOL., vol. 32, 1996, pages 1311 - 1318;;WITTWEHOWARD, BIOCHEM., vol. 29, 1990, pages 4175 - 4180;;WYSSWAGNER, CURRENT OPIN. BIOTECH., vol. 7, 1996, pages 409 - 416;;UMANA ET AL., NATURE BIOTECH, vol. 17, 1999, pages 176 - 180;;TILLER ET AL., J. IMMUNOL. METHODS, vol. 329, 2008, pages 112;;HOOVER, JOHN E.: ""Remington's Pharmaceutical Sciences"", 1975, MACK PUBLISHING CO.;;""Pharmaceutical Dosage Forms"", 1980, MARCEL DECKER;;""Handbook of Pharmaceutical Excipients"", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION;;AGNEW, CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186;;YANG ET AL., MED. RES. REV., vol. 39, 2019, pages 265 - 301;;HASAN M, J IMMUNOL., vol. 162, no. 2, 15 January 1999 (1999-01-15), pages 1064 - 70",PENDING
8,US,A1,US 2020/0126011 A1,089-716-869-697-469,2020-04-23,2020,US 201916582962 A,2019-09-25,US 201916582962 A;;US 201916249705 A;;US 201414289596 A;;US 201461923189 P;;US 201461923187 P,2014-01-02,COMPUTER-IMPLEMENTED METHODS AND SYSTEMS FOR ANALYZING HEALTHCARE DATA,"Computer-implemented systems and methods are provided for analyzing healthcare-related entity performance. In one implementation, a method is implemented with one or more processors and includes receiving a request that includes one or more filter selections and accessing a data structure including information that specifies a plurality of categories of healthcare-related interactions associated with multiple healthcare-related entities. The method also includes identifying a set of categories from the plurality of categories based on the one or more filter selections and processing the information of the identified categories to provide performance information of one or more entities of the multiple healthcare-related entities in accordance with the one or more filter selections. The method further includes generating a user interface that includes the performance information indicating a performance of the one or more entities.",PALANTIR TECHNOLOGIES INC,WANG LEKAN;;CHANG ALLEN;;GARROD JOHN;;IMAN SINA;;TARDIF PATRICK;;LLORCA ANTOINE;;BRUCKNER SEBASTIAN;;VEAL CODY;;FENDELL SAMUEL;;LEWIS CHRISTOPHER;;NGO BRIAN;;DUNN PATRICK;;CALIRI SEBASTIAN;;ARUL HARI;;SUDAN AJAY;;WINLO MICHAEL;;GATENO ISAAC;;GLAZER MICHAEL;;CERVELLI DANIEL;;CHAPARRO LAUREN,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2019-09-23);;PALANTIR TECHNOLOGIES INC (2014-04-24),https://lens.org/089-716-869-697-469,Patent Application,yes,0,0,3,3,0,G06Q10/0639;;G16H40/63;;G16H20/10;;G06Q10/0639;;G16H20/10;;G16H40/63;;G06Q10/10,G06Q10/06;;G06Q10/10;;G16H20/10;;G16H40/63,,0,0,,,,DISCONTINUED
9,US,A1,US 2015/0187036 A1,115-048-786-274-698,2015-07-02,2015,US 201414289596 A,2014-05-28,US 201414289596 A;;US 201461923187 P;;US 201461923189 P,2014-01-02,COMPUTER-IMPLEMENTED METHODS AND SYSTEMS FOR ANALYZING HEALTHCARE DATA,"Computer-implemented systems and methods are provided for analyzing healthcare-related entity performance. In one implementation, a method is implemented with one or more processors and includes receiving a request that includes one or more filter selections and accessing a data structure including information that specifies a plurality of categories of healthcare-related interactions associated with multiple healthcare-related entities. The method also includes identifying a set of categories from the plurality of categories based on the one or more filter selections and processing the information of the identified categories to provide performance information of one or more entities of the multiple healthcare-related entities in accordance with the one or more filter selections. The method further includes generating a user interface that includes the performance information indicating a performance of the one or more entities.",PALANTIR TECHNOLOGIES INC,WANG LEKAN;;CHANG ALLEN;;GARROD JOHN;;IMAN SINA;;TARDIF PATRICK;;LLORCA ANTOINE;;BRUCKNER SEBASTIAN;;VEAL CODY;;FENDELL SAMUEL;;LEWIS CHRISTOPHER;;NGO BRIAN;;DUNN PATRICK;;CALIRI SEBASTIAN;;ARUL HARI;;SUDAN AJAY;;WINLO MICHAEL;;GATENO ISAAC;;GLAZER MICHAEL;;CERVELLI DANIEL;;CHAPARRO LAUREN,PALANTIR TECHNOLOGIES INC (2014-04-24),https://lens.org/115-048-786-274-698,Patent Application,yes,5,175,3,3,0,G06Q10/0639;;G16H40/63;;G16H20/10;;G06Q10/0639;;G16H20/10;;G16H40/63;;G06Q10/10,G06Q10/10;;G16H20/10;;G16H40/63,,2,0,,,"Definition, ""identify"" downloaded on 1/22/2015;;Definition, ""overlay"" downloaded on 1/22/2015",DISCONTINUED
10,US,A1,US 2015/0186821 A1,195-288-005-910-722,2015-07-02,2015,US 201414289599 A,2014-05-28,US 201414289599 A;;US 201461923187 P;;US 201461923189 P,2014-01-02,COMPUTER-IMPLEMENTED METHODS AND SYSTEMS FOR ANALYZING HEALTHCARE DATA,"Computer-implemented systems and methods are provided for analyzing healthcare-related entity performance. In one implementation, a method is implemented with one or more processors and includes accessing a data structure including information that specifies healthcare-related interactions and identifying, from the data structure, a first set of interactions associated with a first healthcare-related entity. The method also includes identifying, from the data structure, a second set of interactions associated with one or more filter selections and processing the information of the identified first and second set of interactions to provide performance information of the first healthcare-related entity and one or more healthcare-related entities associated with the one or more filter selections. The method also includes generating a user interface that includes the performance information of the first healthcare-related entity and the one or more healthcare-related entities indicating a performance of the first healthcare-related entity and the one or more healthcare-related entities respectively.",PALANTIR TECHNOLOGIES INC,WANG LEKAN;;CHANG ALLEN;;GARROD JOHN;;IMAN SINA;;TARDIF PATRICK;;LLORCA ANTOINE;;BRUCKNER SEBASTIAN;;VEAL CODY;;FENDELL SAMUEL;;LEWIS CHRISTOPHER;;NGO BRIAN;;DUNN PATRICK;;CALIRI SEBASTIAN;;ARUL HARI;;SUDAN AJAY;;WINLO MICHAEL;;GATENO ISAAC;;GLAZER MICHAEL;;CERVELLI DANIEL;;CHAPARRO LAUREN,,https://lens.org/195-288-005-910-722,Patent Application,yes,5,174,3,3,0,G06Q10/0639;;G16H40/63;;G16H20/10;;G06Q10/0639;;G16H20/10;;G16H40/63;;G06Q10/10,G16H20/10;;G06Q10/06;;G16H40/63,,0,0,,,,DISCONTINUED
11,US,B2,US 11850809 B2,154-614-989-751-843,2023-12-26,2023,US 202117524561 A,2021-11-11,US 202117524561 A;;US 201815944249 A;;US 201514794634 A,2015-07-08,System for producing a fully impregnated thermoplastic prepreg,"According to one embodiment, a system for manufacturing a fully impregnated thermoplastic prepreg includes a mechanism for moving a fabric or mat and a drying mechanism that removes residual moisture from at least one surface of the fabric or mat. The system also includes a resin application mechanism that applies a reactive resin to the fabric or mat and a press mechanism that presses the coated fabric or mat to ensure that the resin fully saturates the fabric or mat. The system further includes a curing oven through which the coated fabric or mat is moved to polymerize the resin and thereby form a thermoplastic polymer so that upon exiting the oven, the fabric or mat is fully impregnated with the thermoplastic polymer. During at least a portion of the process, humidity in the vicinity of the coated fabric or mat is maintained at substantially zero.",JOHNS MANVILLE,ZHANG MINGFU;;GLEICH KLAUS FRIEDRICH;;YOHANNES ASHEBER;;BLOCK MICHAEL JOHN;;ASRAR JAWED;;BRISTOL DEREK COOPER;;SANDOVAL CHRISTOPHER P;;WALP MATTHEW;;CHAPARRO-CHAVEZ EDWING;;KUKATIN STANISLAV O;;FAULKINBURY ALBERT PATRICK;;MCBRIDE CHRISTOPHER;;LOCKWOOD BRADLEY RAY;;FITZPATRICK NICHOLAS GENE,JOHNS MANVILLE (2015-07-14),https://lens.org/154-614-989-751-843,Granted Patent,yes,18,0,6,19,0,B29B15/122;;C08J3/242;;C08J3/247;;C08L77/02;;Y10T442/2992;;B05D3/0227;;B05D3/0272;;B05D1/26;;B05D2201/02;;B05D2252/02;;C08G69/16;;B29B13/06;;B29B13/02;;C08J5/244;;B29C70/50;;B29C70/502;;B29C70/504;;D06M23/00;;D06M15/715;;D06N3/0086;;Y10T442/2992;;B05C5/0245;;B05C5/0254;;B05C9/10;;B05C9/12;;B05C9/14;;B05C11/021;;B05D1/40;;B05D3/0227;;B05D3/0272;;B29B11/12;;B29B11/16;;B29B13/02;;B29B13/06;;B29B15/12;;B29B15/122;;B29B15/14;;B29C70/06;;B29C70/50;;B29C70/504;;B29K2033/12;;B29K2105/0872;;B29K2105/089;;B29K2105/256;;B29L2007/002;;B29L2009/00;;B32B5/28;;C08J3/242;;C08J3/247;;C08J5/24;;C08K7/14;;C08L77/02;;D06M15/51;;D06M15/61;;D06M15/705;;D06M15/71,B29C70/50;;B05C5/02;;B05C9/10;;B05C9/12;;B05C9/14;;B05C11/02;;B05D1/40;;B05D3/02;;B29B11/12;;B29B11/16;;B29B13/02;;B29B13/06;;B29B15/12;;B29B15/14;;B29C70/06;;B29K33/00;;B29K105/00;;B29K105/08;;B29L7/00;;B29L9/00;;B32B5/28;;C08J3/24;;C08J5/24;;C08K7/14;;C08L77/02;;D06M15/51;;D06M15/61;;D06M15/705;;D06M15/71,,0,0,,,,ACTIVE
12,WO,A1,WO 2023/218320 A1,047-133-415-069-697,2023-11-16,2023,IB 2023054754 W,2023-05-08,US 202263340753 P,2022-05-11,ANTI-LYMPHOTOXIN BETA RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF,"Antibodies that specifically bind to LTBR are provided. Also provided are uses of these antibodies, and related compositions and methods.",PFIZER,APGAR JAMES REASONER;;SALEK-ARDAKANI SHAHRAM;;BAATEN BAS JOANNES GERTRUDIS;;BITRA ARUNA;;CHAPARRO RIGGERS JAVIER FERNANDO;;DI CARO GIUSEPPE;;DOMINIK PAWEL KAMIL;;MABEN ZACHARY JOHN;;MOSYAK LIDIA;;NAGER ANDREW ROSS;;ODERUP CECILIA MARIANNE;;PASCUA EDWARD DERRICK;;ZAJONC DIRK MICHAEL,,https://lens.org/047-133-415-069-697,Patent Application,yes,26,0,2,2,22,C07K16/2878;;A61P35/00;;C07K2317/76;;C07K2317/75;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K16/22;;C07K2317/55;;C07K2317/33;;C07K2317/34;;C07K2317/64;;C07K2317/35;;A61P35/00;;A61K2039/505;;C07K16/2878;;C07K2317/35;;C07K2317/71;;C07K2317/92,A61P35/00;;C07K16/22;;C07K16/28,,62,40,013-765-217-954-646;;027-211-316-354-842;;017-660-137-487-27X;;021-202-759-329-205;;047-290-545-287-720;;173-572-222-412-05X;;017-150-654-990-340;;049-134-753-209-354;;008-274-774-541-556;;004-529-618-392-612;;156-501-805-490-709;;099-423-776-471-288;;076-090-519-318-074;;004-891-036-744-106;;002-264-966-090-625;;024-995-475-936-443;;023-868-377-007-810;;019-130-383-424-869;;005-018-877-991-494;;106-753-778-592-300;;030-630-100-818-462;;002-007-578-507-698;;068-264-897-850-380;;104-214-218-664-008;;072-509-376-457-062;;010-488-381-022-259;;013-452-637-389-025;;017-216-732-209-839;;000-513-978-398-020;;054-717-629-774-351;;057-945-343-734-358;;002-237-818-610-496;;017-598-779-633-254;;083-695-147-039-802;;127-144-904-319-750;;031-391-134-339-145;;070-318-112-524-781;;049-265-891-179-763;;031-605-709-605-848;;006-624-122-050-705,10.1038/s41568-019-0144-6;;31092904;;10.1016/s1074-7613(01)00094-2;;10.1016/s1074-7613(09)00094-6;;11239444;;17605009;;10.1007/s00262-007-0352-x;;28892469;;10.1038/ni.3836;;10.1016/j.ccell.2016.02.004;;pmc4794755;;26977880;;7561440;;3140379;;10.1126/science.3140379;;10.1016/0022-2836(87)90412-8;;3681981;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;8069524;;10.1006/immu.1994.1004;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;10.1002/(sici)1097-0134(1999)37:3+<194::aid-prot24>3.3.co;2-6;;10.1002/(sici)1097-0134(1999)37:3+<194::aid-prot24>3.0.co;2-f;;9143687;;10.1146/annurev.immunol.15.1.203;;10592229;;pmc102431;;10.1093/nar/28.1.214;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/342877a0;;2687698;;2594766;;pmc298475;;10.1073/pnas.86.23.9268;;17947238;;10.1074/jbc.m706190200;;10.1073/pnas.63.1.78;;5257969;;pmc534037;;1172191;;10.1038/256495a0;;10.1038/348552a0;;2247164;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;10.4049/jimmunol.117.2.587;;950463;;10.1016/s0167-5699(97)01172-9;;9425738;;10.1038/nbt0797-637;;9219265;;14699147;;10.1074/jbc.c300470200;;8943402;;10.4049/jimmunol.157.11.4963;;10.1016/0196-8858(81)90046-4;;7490135;;pmc1384012;;10.4049/jimmunol.164.8.4178;;10754313;;2507634;;10.4049/jimmunol.143.8.2595;;9700502;;10.1111/j.1600-065x.1998.tb01188.x;;10.1159/000319352;;10.1159/000425635;;9018875;;10.1016/0161-5890(95)00118-2;;8643100;;10.1021/bi00469a021;;2141793;;10.1016/s0958-1669(96)80116-9;;8768899;;10.1038/6179;;10052355;;pmc3123872;;21703392;;10.1016/j.ajpath.2011.03.007;;10.1016/j.jim.2007.09.017;;pmc2243222;;17996249;;10.1002/med.21530;;30215856,"SAUTES-FRIDMAN, C ET AL., NAT REV CANCER, no. 6, 19 June 2019 (2019-06-19), pages 307 - 325;;HELMINK B ET AL., NATURE, vol. 77, no. 7791, 5 January 2020 (2020-01-05), pages 549 - 555;;SCHRAMA D ET AL., IMMUNITY, no. 2, 14 February 2001 (2001-02-14), pages 111 - 21;;LUKASHEV, M ET AL., CANCER RES, vol. 6, no. 19, 6 October 2006 (2006-10-06);;SCHRAMA D ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 7, no. 1, 5 January 2008 (2008-01-05), pages 85 - 95;;JOHANSSON-PERCIVAL A ET AL., NAT IMMUNOL, no. 11, 18 November 2017 (2017-11-18), pages 1207 - 1217;;TANG HETAL, CANCER CELL, vol. 29, no. 3, 14 March 2016 (2016-03-14), pages 285 - 296;;ALLEN E ET AL., SCI TRANSL MED, vol. 9, no. 385, 12 April 2017 (2017-04-12), pages eaak9769;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;""CURRENT PROTOCOLS IN MOLECULAR BIOLOGY"", 2003;;HAAS ET AL., J. LAB. CLIN. MED., vol. 126, 1995, pages 330 - 41;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;CHOTHIALESK, J MOL BIOL, vol. 196, no. 4, 1987, pages 901 - 917;;""Oligonucleotide Synthesis"", 1984;;CLYNES ET AL., PROC. NATL. ACAD. SCI. (USA, vol. 95, 1998, pages 652 - 656;;""Cell and Tissue Culture Laboratory Procedures"", 1993, J. WILEY AND SONS;;CAPELET, IMMUNOMETHODS, vol. 4, 1994, pages 25 - 34;;RAVETCHKINET, ANNU. REV. IMMUNOL, vol. 9, 1991, pages 457 - 92;;SAMUDRALA ET AL.: ""Ab Initio Protein Structure Prediction Using aCombined Hierarchical Approach"", PROTEINS, STRUCTURE, FUNCTION AND GENETICS SUPPL., vol. 3, 1999, pages 194 - 198, XP001146416;;DAERON, ANNU. REV. IMMUNOL., vol. 15, 1997, pages 203 - 234;;JOHNSONWU, NUCLEIC ACIDS RES., vol. 28, 2000, pages 214 - 8;;HUSTON ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 5879 - 5883;;CHOTHIAET, J. MOL. BIOL., vol. 196, 1986, pages 901 - 17;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 83;;MARTIN ET AL., PROC NATL ACAD SCI (USA, vol. 86, 1989, pages 9268 - 9272;;MACCALLUM ET AL., J. MOL. BIOL., vol. 5, 1996, pages 732 - 45;;MAKABE ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, 2008, pages 1156 - 1166;;EDELMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 63, no. 1, 1969, pages 78 - 85;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495;;MCCAFFERTYET, NATURE, vol. 348, 1990, pages 552 - 554;;EUR. J. IMMUNOL., vol. 29, 1999, pages 2613 - 2624;;GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587;;KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249;;GHETIEWARD, IMMUNOL. TODAY, vol. 18, no. 12, 1997, pages 592 - 598;;GHETIE ET AL., NATURE BIOTECHNOLOGY, vol. 15, no. 7, 1997, pages 637 - 640;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;METHODS IN ENZYMOLOGY, vol. 266;;LUND ET AL., J. IMMUNOLOGY, vol. 157, 1996, pages 4963 - 9;;METH. MAL. BIOL., vol. 70, 1997, pages 173 - 187;;J. MAL. BIOL., vol. 48, 1970, pages 443 - 453;;SMITHWATERMAN, ADVANCES IN APPLIED MATHEMATICS, vol. 2, 1981, pages 482 - 489;;""Current Methods in Sequence Comparison and Analysis, Macromolecule Sequencing and Synthesis, Selected Methods and Applications"", 1988, ALAN R. LISS, INC, pages: 127 - 149;;""UniProtKB"", Database accession no. A0A2K5VGQ6;;MORGAN ET AL., IMMUNOLOGY, vol. 86, 1995, pages 319 - 324;;IDUSOGIE ET AL., J. IMMUNOLOGY, vol. 164, 2000, pages 4178 - 4184;;TAO ET AL., J. IMMUNOLOGY, vol. 143, 1989, pages 2595 - 2601;;JEFFERIS ET AL., IMMUNOLOGICAL REVIEWS, vol. 163, 1998, pages 59 - 76;;JEFFERISLUND, CHEM. IMMUNOL., vol. 65, 1997, pages 111 - 128;;WRIGHTMORRISON, TIBTECH, vol. 15, 1997, pages 26 - 32;;BOYD ET AL., MOL. IMMUNOL., vol. 32, 1996, pages 1311 - 1318;;WITTWEHOWARD, BIOCHEM., vol. 29, 1990, pages 4175 - 4180;;WYSSWAGNER, CURRENT OPIN. BIOTECH., vol. 7, 1996, pages 409 - 416;;UMANA ET AL., NATURE BIOTECH., vol. 17, 1999, pages 176 - 180;;SCHUMACHER ET AL., SCIENCE, vol. 375, 2022, pages 39;;COPPOLA ET AL., AM J. PATHOL, vol. 179, 2011, pages 37;;MESSINAET AL. SCIENTIFIC REPORT, vol. 2, 2012, pages 765;;TILLER ET AL., J. IMMUNOL. METHODS, vol. 329, 2008, pages 112;;HOOVER, JOHN E.: ""Remington's Pharmaceutical Sciences"", 1975, MACK PUBLISHING CO.;;""Pharmaceutical Dosage Forms"", 1980, MARCEL DECKER;;""Handbook of Pharmaceutical Excipients"", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION;;AGNEW, CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186;;YANG ET AL., MED. RES. REV., vol. 39, 2019, pages 265 - 301",PENDING
13,US,A1,US 2023/0365701 A1,076-951-118-133-548,2023-11-16,2023,US 202318315054 A,2023-05-10,US 202318315054 A;;US 202263340753 P,2022-05-11,ANTI-LYMPHOTOXIN BETA RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF,"Antibodies that specifically bind to LTBR are provided. Also provided are uses of these antibodies, and related compositions and methods.",PFIZER,APGAR JAMES REASONER;;BAATEN BAS JOANNES GERTRUDIS;;BITRA ARUNA;;CHAPARRO RIGGERS JAVIER FERNANDO;;DI CARO GIUSEPPE;;DOMINIK PAWEL KAMIL;;MABEN ZACHARY JOHN;;MOSYAK LIDIA;;NAGER ANDREW ROSS;;ODERUP CECILIA MARIANNE;;PASCUA EDWARD DERRICK;;SALEK-ARDAKANI SHAHRAM;;ZAJONC DIRK MICHAEL,,https://lens.org/076-951-118-133-548,Patent Application,yes,0,0,2,2,0,C07K16/2878;;A61P35/00;;C07K2317/76;;C07K2317/75;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K16/22;;C07K2317/55;;C07K2317/33;;C07K2317/34;;C07K2317/64;;C07K2317/35;;A61P35/00;;A61K2039/505;;C07K16/2878;;C07K2317/35;;C07K2317/71;;C07K2317/92,A61P35/00;;C07K16/28,,0,0,,,,PENDING
